Medical Oncology Department, Josep Trueta Universitary Hospital, Catalan Institute of Oncology, Av de França, 17007 Girona, Spain.
Descriptive Epidemiology, Genetics and Cancer Prevention Group, Biomedical Research Institute (IDIBGI), C/Dr. Castany, s/n, 17190 Salt, Spain.
Int J Environ Res Public Health. 2020 Dec 19;17(24):9538. doi: 10.3390/ijerph17249538.
(1) Background: We investigated the incidence and survival trends for pancreatic cancer (PC) over the last 25 years in the Girona region, Catalonia, Spain; (2) Methods: Data were extracted from the population-based Girona Cancer Registry. Incident PC cases during 1994-2015 were classified using the International Classification of Diseases for Oncology Third Edition (ICD-O-3). Incidence rates age-adjusted to the European standard population (ASR) and world standard population (ASR) were obtained. Trends were assessed using the estimated annual percentage of change (EAPC) of the ASR Observed and relative survivals (RS) were estimated with the Kaplan-Meier and Pohar Perme methods, respectively; (3) Results: We identified 1602 PC incident cases. According to histology, 44.4% of cases were exocrine PC, 4.1% neuroendocrine, and 51.1% malignant-non-specified. The crude incidence rate (CR) for PC was 11.43 cases-per-100,000 inhabitants/year. A significant increase of incidence with age and over the study period was observed. PC overall 5-year RS was 7.05% (95% confidence interval (CI) 5.63; 8.84). Longer overall survival was observed in patients with neuroendocrine tumours (5-year RS 61.45%; 95% CI 47.47; 79.55). Trends in 5-year RS for the whole cohort rose from 3.27% (95% CI 1.69-6.35) in 1994-1998 to 13.1% (95% CI 9.98; 17.2) in 2010-2015; (4) Conclusions: Incidence rates of PC in Girona have increased in the last two decades. There is a moderate but encouraging increase in survival thorough the study period. These results can be used as baseline for future research.
(1)背景:我们研究了过去 25 年在西班牙加泰罗尼亚的赫罗纳地区胰腺癌(PC)的发病率和生存趋势;(2)方法:数据从基于人群的赫罗纳癌症登记处提取。1994-2015 年间发生的 PC 病例根据国际肿瘤疾病分类第 3 版(ICD-O-3)进行分类。获得了年龄调整至欧洲标准人口(ASR)和世界标准人口(ASR)的发病率。使用观察到的年度百分比变化(EAPC)评估趋势,并分别使用 Kaplan-Meier 和 Pohar Perme 方法估计相对生存率(RS);(3)结果:我们确定了 1602 例 PC 发病病例。根据组织学,44.4%的病例为外分泌性 PC,4.1%为神经内分泌,51.1%为恶性未特指。PC 的粗发病率(CR)为 11.43 例/10 万居民/年。观察到发病率随年龄和研究期间的显著增加。PC 总 5 年 RS 为 7.05%(95%置信区间[CI] 5.63;8.84)。神经内分泌肿瘤患者的总体生存时间较长(5 年 RS 61.45%;95%CI 47.47;79.55)。整个队列的 5 年 RS 趋势从 1994-1998 年的 3.27%(95%CI 1.69-6.35)上升到 2010-2015 年的 13.1%(95%CI 9.98;17.2);(4)结论:在过去的二十年中,赫罗纳的 PC 发病率有所增加。在整个研究期间,生存率呈适度但令人鼓舞的增长。这些结果可用作未来研究的基线。